Realizing Effectiveness Across Continents With Hydroxyurea — REACH  

Sickle Cell Disease Clinical Trial

Official title: Realizing Effectiveness Across Continents With Hydroxyurea: A Phase I/II Prospective Trial of Hydroxyurea for Children With Sickle Cell Anemia

Status Recruiting

Clinical Trial Summary

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.

Clinical Trial Description

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs. In the REACH prospective trial, the Original Cohort will receive long-term treatment while for the New Cohort, treatment will continue at least 4 years using PK-guided dosing after an initial 3-month screening period. ;

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Children
• Sickle Cell Disease

• NCT number: NCT06171217
• Study type: Interventional
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: Russell Ware, MD, PhD
• Phone: 513-803-4597
• Email: russell.ware@cchmc.org
• Status: Recruiting
• Phase: Phase 2
• Start date: October 27, 2023
• Completion date: October 4, 2033